Thursday, October 22, 2026

Earnings & Performance

4 articles

SunPower Gross Profit Falls 41% to $27.6M as Revenue Drops Only 23%

SunPower Gross Profit Falls 41% to $27.6M as Revenue Drops Only 23%

SunPower's gross profit fell 41% to $27.6 million in Q2 2026, from $46.9 million a year earlier, while revenue declined only 23%, from $73 million to $56 million. The gap signals margin erosion outpacing the sales decline, a problem new CFO Tom Kowalczuk now faces.

LM Salvado•
Principal Financial Posts Record $37B Q1 Sales as Traditional Banks Cut Costs Ahead of Macro Slowdown

Principal Financial Posts Record $37B Q1 Sales as Traditional Banks Cut Costs Ahead of Macro Slowdown

Principal Financial Group reported $37 billion in Q1 2026 gross investment management sales, up 21% year-over-year, with operating ROE hitting 16.1%. The result sharpens a growing divide between institutional asset managers and traditional banks, which are reducing headcount as GDP growth forecasts fall below 1% for H2 2026. Regional lenders like CVB Financial navigate post-merger integration while commercial real estate headwinds pressure credit portfolios.

LM Salvado•
Algorithm Changes at Ad Platforms Trigger Revenue Volatility for AI-Powered Beauty Tech

Algorithm Changes at Ad Platforms Trigger Revenue Volatility for AI-Powered Beauty Tech

AI-driven advertising algorithm changes at major platforms are creating significant revenue swings for direct-to-consumer beauty tech companies. ODDITY Tech expects Q1 2026 revenue to decline following algorithmic disruptions at its largest advertising partner, demonstrating how platform changes can impact AI-powered retail models.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com